亚太心脏泵设备市场 – 行业趋势及 2030 年预测

亚太心脏泵设备市场分析及规模

行业参与者不断开发新产品、老年人口增加以及心血管疾病患病率上升推动了市场的发展。心脏泵设备是一种实用的替代方案，由于缺乏心脏捐赠者，导致全球市场增长。捐赠者供需之间巨大的不匹配，以及预测期内批准了许多新型尖端心脏泵设备。

Data Bridge Market Research 分析，心脏泵设备市场在 2022 年的规模为 31.9 亿美元，预计到 2030 年将达到 110.9 亿美元，在 2023 年至 2030 年的预测期内的复合年增长率为 16.85%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

亚太心脏泵设备市场范围和细分  

市场定义

The basic purpose of heart pump systems is to improve heart blood flow. They have different applications. A popular phrase in relation to heart pumps is "ventricular help gadget." For the left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device, a few different types of heart pumps are available (BiVAD). The left ventricular assist device, which enables the left ventricular to pump blood to the aorta, is the most frequently employed of these. The right ventricular assist device only provides brief assistance so that the right ventricle can pump blood into the pulmonary artery. The heart pump device market is growing due to the increasing prevalence of cardiovascular diseases.

Asia-Pacific Heart Pump Devices Market Dynamics

Drivers

• Increasing prevalence of cardiovascular diseases

The main behavioural risk factors for heart disease and stroke include poor eating habits, inactivity, cigarette use, and alcohol abuse. As a result of behavioural risk factors, people may develop high blood pressure, high blood sugar, high blood lipids, overweight, and obesity. In low- and middle-income countries, CVD-related deaths account for at least 75% of all fatalities. People who live in low- and middle-income countries usually lack access to the benefits of primary health care programmes for the early detection and treatment of patients with risk factors for cardiovascular diseases (CVDs). Low- and middle-income nations have limited access to effective and fair health care services that can meet their demands for people with no communicable illnesses and CVDs. As a result, these factors propel the market growth.

• Huge geriatric population

The world's geriatric population is enormous. They account for approximately 16% of the total population. The prevalence of diseases is higher in the elderly, and heart disease is no exception. The large geriatric population and the higher prevalence of heart diseases and heart failures in the elderly are driving the heart pump devices market. The geriatric population is expected to reach 2.1 billion by 2050. As a result, this factor boosts the growth of market.

Opportunities

• Long waiting period for heart transplant surgery

The rising prevalence of CVDs and heart failure in recent years has resulted in a significant increase in the demand for heart transplants. However, there is a scarcity because there are not enough hearts for transplantation to meet the demand. When a patient is not a candidate for a heart transplant, these devices can provide them with the assistance they require while they wait. In this context, the market for heart pump devices is expected to grow during the forecast period due to the significant gap between donor's heart demand and availability.

Restraints/Challenges

• Complications related to LVAD implantations

Ventricular support devices, particularly left ventricular assist devices (LVADs), are frequently used in bridge-to-heart transplantation. Although LVADs are thought to be life-saving devices, they do have several drawbacks. Up to 60% of patients typically experience LVAD-related problems six months after implantation. Nearly 80% of patients had at least one unfavourable incident within two years. Unexpected hospital readmissions are common. Patients are readmitted an average of 2.2 times over the course of their median follow-up period of 11 months.

Non-surgical adverse events associated with LVAD include device thrombosis, bleeding problems, renal impairment, ischemic and hemorrhagic strokes, multi-organ failure, and infections. Approximately 60% of VAD patients develop an infection within 90 days. Infections, thromboembolic events, and bleeding problems are just a few of the common LVAD side effects. These all are the factors which hamper the market growth.

This heart pump devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the heart pump devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, The FDA granted CARMAT permission to conduct an Early Feasibility Study (EFS) of its TAH in the United States.
• In 2020, The FDA approved the amended labeling for Abbott's Heart Mate 3 Heart Pump for use in juvenile patients with advanced refractory left ventricular heart failure.

Asia-Pacific Heart Pump Devices Market Scope

The heart pump devices market is segmented on the basis of product, type, therapy and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Ventricular Assist Devices
• Left ventricular assist devices
• Right ventricular assist devices
• Bi-ventricular assist devices
• Percutaneous ventricular assist devices
• Intra-Aortic Balloon Pumps
• Total Artificial Heart

 Type

• Implantable Heart Pump Devices
• Extracorporeal Heart Pump Devices

 Therapy

• Bridge-To-Candidacy (BTC)
• Bridge-To-Transplant (BTT)
• Destination Therapy (DT)
• Other Therapies

 End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics, Research Institutes

Heart Pump Devices Market Regional Analysis/Insights

对心脏泵设备市场进行了分析，并按国家、产品、类型、疗法和最终用户提供了市场规模洞察和趋势，如上所述。

心脏泵设备市场报告涵盖的国家包括亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾和亚太地区 (APAC) 其他地区。

由于该地区拥有完善的医疗保健基础设施和优惠的报销政策，中国在心脏泵设备市场占据主导地位。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

心脏泵设备市场还为您提供详细的市场分析，包括每个国家/地区资本设备医疗支出的增长、心脏泵设备市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗监管情景的变化及其对心脏泵设备市场的影响。数据涵盖 2011-2021 年的历史时期。

竞争格局和心脏泵设备市场份额分析

心脏泵设备市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对心脏泵设备市场的关注有关。

心脏泵设备市场的一些主要参与者包括：

• 雅培（美国）
• Getinge AB（瑞典）
• Teleflex Incorporated（美国）
• ABIOMED（美国）
• 柏林之心（德国）
• BiVACOR Inc.（美国）
• Calon Cardio-Technology Ltd（英国）
• CardiacAssist, Inc（美国）
• Jarvik Heart, Inc（美国）
• 美敦力（爱尔兰）
• SynCardia Systems, LLC（美国）
• 泰尔茂株式会社 (日本)
• 费森尤斯医疗保健股份公司（德国）
• CARMAT（法国）

SKU-24437